Announcement on Using Temporarily Idle Raised Funds for Cash Management
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
-- Announcement on Using Temporarily Idle Raised Funds for Cash Management
Filed with SSE · · 5 pages · Chinese
Release
CanSino Biologics, Inc. on 6ix
Earlier from CanSino Biologics
- -- Announcement on Obtaining Notice of Approval for Drug Clinical Trial for Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell)
- Announcement on the Obtainment of Drug Registration Certificate for 13-valent Pneumococcal Polysaccharide Vaccine (CRM197/Tetanus Toxoid)
- Announcement on Resolution of the 2024 Annual General Meeting
- Voluntary Disclosure on the Approval of Clinical Trial for Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) in Indonesia
- Notice on Convening the 2024 Annual General Meeting
Later from CanSino Biologics
- -- Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction and Semi-annual Report Performance Briefing
- -- Announcement on Resolutions of the 9th Meeting of the 3rd Board of Supervisors
- Board of Supervisors' Remarks on Publicity of and Verification Opinions on List of Incentive Objects Initially Granted under 2025 A-share Restricted Stock Incentive Plan
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
- Announcement on Adjusting Matters Related to the 2025 A-share Restricted Stock Incentive Plan
Follow CanSino Biologics into a list and get an email when it puts out news.
Follow CanSino Biologics